Global neoantigen targeted therapies market size reached USD 1.76 billion in 2021 and is expected to register a revenue CAGR of 37.3% during the forecast period, according to latest analysis by Emergen Research. Increasing incidence of malignant tumors and rising prevalence of cancer are some key factors expected to support market revenue growth between 2022 and 2030.
The process of tumor formation results in expression of certain novel protein molecules on the surface of the cancerous cells, known as neoantigens. The proteins are being used in the healthcare sector to strengthen patient immune system and elicit a strong immunogenic response against cancer cells. Optimized polyepitope nucleic acid vaccines are under development to be used as immunotherapies for treatment of several types of cancer. This has increased the adoption of such therapies and is expected to further boost revenue growth of the market during the forecast period.
Visit the link below: https://www.emergenresearch.com/industry-report/neoantigen-targeted-therapies-market
Geographical Segmentation:
The latest research report entails an in-depth analysis of the current growth opportunities for various regions of the Neoantigen Targeted Therapies Market, gauging their revenue share over the forecast timeline. Furthermore, the report analyses the year-on-year growth rate of these regions over the forecast duration. The leading market regions profiled in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Market Overview:
The research report on the Neoantigen Targeted Therapies market is formulated through extensive primary and secondary research along with qualitative and quantitative analysis of vital aspects of the market. The insightful data is further validated and verified by the industry professionals. The report strives to offer deeper insights into the overall market scenario of the Neoantigen Targeted Therapies business sphere.
Key Companies in the global market report include BioNTech SE, Gritstone Bio, Inc., Genocea Biosciences, Moderna, Inc., Agenus, Inc., Immatics N.V., Advaxis, Inc., Precision Biologics, Inc., Gilead Sciences, Inc., Cellular Biomedicine Group, Inc., Achilles Therapeutics Plc, and Merck & Co., Inc.
Emergen Research has segmented the global neoantigen targeted therapies market on the basis of target disease indication, neoantigen type, immunotherapy type, and region:
· Target Disease Indication Outlook (Revenue, USD Billion, 2019–2030)
· Neoantigen Type Outlook (Revenue, USD Billion, 2019–2030)
· Immunotherapy Type Outlook (Revenue, USD Billion, 2019–2030)
The report addresses the following key points:
Thank you for reading our report. Customization of the report is available. To know more, please connect with us, and our team will ensure the report is customized as per your requirements.
About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Media ContactCompany Name: Emergen ResearchContact Person: Eric LeeEmail: Send EmailPhone: +1 (604) 757-9756Address:14671 110 Avenue Surrey, British Columbia, V3R2A9City: SurreyState: British ColumbiaCountry: CanadaWebsite: https://www.emergenresearch.com/industry-report/metaverse-in-finance-market